Scott Gottlieb
Independent DirectorDr. Scott Gottlieb, M.D., serves as Independent Director at UnitedHealth Group Incorporated since November 18, 2025. He serves as Board Member at Pfizer Venture Investments LLC. He is Director of Xaira Therapeutics, Inc. Dr. Gottlieb is Director of Comanche Biopharma Corp. since January 17, 2024. He served as a Director at Totus Medicines Inc. and National Resilience, Inc. Dr. Gottlieb has held roles at the Centers for Medicare & Medicaid Services and on the Federal Health Information Technology Policy Committee. He served as PArtner at NEA Management Company LLC from January 2007 to May 2017. He has been Member of Scientific Advisory Board at CellCarta (formerly, CellCarta Precision Medicine Inc. (formerly known as Caprion Proteomics, Inc.).). Dr. Gottlieb serves as Independent Director at Tempus AI, Inc. since October 2019. Dr. Gottlieb has been an Independent Director of Illumina, Inc. since February 4, 2020 & serves as it's Chairman since March 28, 2025. Dr. Gottlieb serves as Director at Pfizer Inc. since June 27, 2019. Dr. Gottlieb serves as Partner at New Enterprise Associates, Inc since May 22, 2019. At the firm, he is a part of the healthcare investment team and focuses on Seed/Early, Growth, Healthcare, US. He had been a Venture Partner at New Enterprise Associates since 2007 till 2017. Prior to joining the firm, he served as the Commissioner of the U. S. Food and Drug Administration (FDA) from May 2017 to April 2019. Dr. Gottlieb is a physician, policy expert and advocate for healthcare entrepreneurship, innovation and access and is focused on advancing public health to improve medical outcomes, reshaping healthcare delivery and expanding consumer choice and safety. He helped oversee a modernization of the FDA's new drug and medical device review programs and historic reorganization of the agency's field operations; and led the passage and implementation of significant new legislation, including new bills to address the opioid crisis and expand the agency's user fee programs. He served as a Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services. Dr. Gottlieb promoted new platforms for advancing medical product safety and presided over a 20 percent increase in the agency's budget over few years. Dr. Gottlieb has been a Managing Director at TRW since 2013. He serves as a Senior Policy Maker of United States Food and Drug Administration. Dr. Gottlieb served as a Senior Adviser of Arcoda Investment Management, LLC from 2007 to 2012 and as a Member to several decision making boards at GlaxoSmithKline from 2010 to 2013 including serving as a Member of its Product Investment Board. He serves as a Commissioner of the U. S. Food and Drug Administration. He has been Director of Aetion, Inc. since 2019. He served as Deputy Commissioner for Medical and Scientific Affairs of United States Food and Drug Administration (FDA) from 2005 to February 2007. He joined FDA in July 2005. He served at the Agency in a number of senior capacities, including Senior Advisor for Medical Technology for the FDA Commissioner and Director of Medical Policy Development from 2003 to 2004. He served as Senior Advisor to the CMS Administrator. Prior to FDA, he held a number of writing and editorial positions, including serving as a columnist at Forbes. com, staff writer for the British Medical Journal and Senior Editor of Pulse, a section of the Journal of the American Medical Association. He served as a Healthcare Analyst for the investment bank Alex Brown & Sons. He left the FDA in 2004 to work on implementation of the new Medicare Drug Benefit as a Senior Adviser to the Administrator of Medicare and Medicaid Services, where he supported the agency's policy work on quality improvement and coverage and payment decision-making, particularly related to new medical technologies. Dr. Gottlieb also served as Chief Policy Advisor to CMS Administrator. He served as Member of Scientific and Strategic Advisory Group at ReNeuron Group plc. He served as a Director of Emmaus Life Sciences, Inc. from August 3, 2015 to December 16, 2015. He served as a Director of Aptiv Solutions, Inc., since September 2012. He serves as a Director at Medavant, CombiMatrix Molecular Diagnostics, Inc., American Pathology Partners, Inc. and MedAvante, Inc. He served as a Director of Gradalis, Inc., since June 4, 2014. He served as an Independent Director of CombiMatrix Corporation from January 15, 2009 to December 19, 2016. He served as a Director of Molecular Insight Pharmaceuticals, Inc. since August 31, 2007 and Bravo Health, Inc. He serves as an editorial Board Member of the journal Value Based Cancer Care and the Food and Drug Law Institute's Policy Forum. Dr. Gottlieb is also a Member of the policy boards to the Leukemia & Lymphoma Society and the Society of Hospitalist Medicine. He also serves as an Advisor to the National Comprehensive Cancer Network and the National Coalition for Cancer Survivorship. He received Visionary in Medicine award by Sarcoma Foundation of America in May 2007, Presidential Commendation for Exceptional Service to People with Pain by American Academy of Pain Medicine in February 2006 and Administrative Recognition of Leadership, Performance and Dedication to the Public Service by Centers for Medicaid and Medicare Services in September 2004. In 2018 and again in 2019, Dr. Gottlieb was recognized by Fortune as one of "The World's 50 Greatest Leaders" and by Time as one of the "50 People Transforming Healthcare." He is a CNBC contributor and his work is frequently published in a wide range of publications and medical journals, including The Wall Street Journal, The New York Times and The Washington Post. Dr. Gottlieb is a recipient of numerous medical association awards, he is the author of more than 300 articles that have appeared in leading medical journals as well as The New York Times, The Wall Street Journal, USA Today and Forbes Magazine. He has also held editorial positions on the British Medical Journal and the Journal of the American Medical Association and appears regularly as a guest commentator on the cable financial news channel CNBC. Dr. Gottlieb also authored the Gilder Biotech Report and the Forbes-Gottlieb Medical Technology Report. Dr. Gottlieb has testified before the House and Senate on issues of regulatory policy and innovation and publishes frequently on these subjects, including recent articles in The Wall Street Journal, Health Affairs, Forbes. com and USA Today. Dr. Gottlieb practices medicine as an attending physician at Stamford Hospital in Connecticut, where he is an Internist on the hospital's inpatient medical wards. He also serves as a Clinical Assistant Professor at the New York University School of Medicine. He is a practicing physician and Resident Fellow at the American Enterprise Institute, where his work is focused on providing insights into the economic, regulatory and technological forces driving the transformation of healthcar
Positions
- Company NamePfizer Inc.Stock CodePFEPositionIndependent DirectorColleagues
- ABAlbert BourlaChairman of the Board & CEO
- CBChris BoshoffChief Scientific Officer and President of Research & Development
- DMDouglas M. LanklerExecutive VP & Chief Legal Officer
- AMAamir MalikExecutive VP & Chief U.S. Commercial Officer
- CGCecile GueganExecutive VP & CFO
- SMSuzanne M. Nora JohnsonIndependent Director
- JCJames C. SmithIndependent Director
- JJJoseph J. EchevarriaIndependent Director
- SGScott GottliebIndependent Director
- Company NameIllumina, Inc.Stock CodeILMNPositionIndependent ChairmanColleagues
- JTJacob ThaysenCEO, President & Director
- SGScott GottliebIndependent Chairman
- ADAnkur DhingraChief Financial Officer
- KCKevin Carl PegelsChief of Global Operations
- SBSteven BarnardChief Technology Officer
- SEScott EricksenVP & Chief Accounting Officer
- SESusan E. SiegelIndependent Director
- SBScott B. UllemIndependent Director
- ASAnna S. RichoIndependent Director
- Company NameTempus AI, Inc.Stock CodeTEMPositionIndependent DirectorColleagues
- EPEric P. LefkofskyCo-Founder, CEO, President & Chairman
- JRJames RogersChief Financial Officer
- EPErik PhelpsExecutive VP and Chief Administrative & Legal Officer
- APAndrew PolovinChief Legal Officer
- RFRyan FukushimaChief Executive Officer of Data & Apps
- PJPeter J. BarrisIndependent Director
- TJTheodore J. LeonsisIndependent Director
- EDEric D. BelcherIndependent Director
